Keyword: Samsung Biologics

Markets & Companies

The CDMO/CMO Report

11.09.2024 -

Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...

News

Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing

26.10.2023 -

Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and...

News

Samsung Biologics and Pfizer in Biosimilars Pact

13.06.2023 -

South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.

News

Pharma CEOs Take Action on Climate Change

08.11.2022 -

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...

News

Samsung Biologics in $81 Million Deal with Novartis

13.06.2022 -

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...

Markets & Companies

Ramping Up Biomanufacturing Capacity

20.04.2022 -

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...

News

Samsung Biologics to Take Control of Bioepis JV

04.02.2022 -

Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will...

News

GSK in Manufacturing Pact with Samsung Biologics

25.05.2020 - GlaxoSmithKline has agreed an eight-year, $231 million, pact with South Korean CDMO Samsung Biologics to scale up manufacturing of biologics. The capacity Samsung provides will be...